Selected article for: "acid valproic and acute respiratory"

Author: Sher, Yelizaveta; Rabkin, Beatrice; Maldonado, Jose R.; Mohabir, Paul
Title: A CASE REPORT OF COVID-19 ASSOCIATED HYPERACTIVE ICU DELIRIUM WITH PROPOSED PATHOPHYSIOLOGY AND TREATMENT
  • Cord-id: mr239gai
  • Document date: 2020_5_19
  • ID: mr239gai
    Snippet: There have been increasing reports of neuropsychiatric presentations and symptoms of COVID-19, more commonly seen in severely ill patients. Delirium, which is highly prevalent in general intensive care unit (ICU) populations, is expected to be frequent and prominent in COVID-19 patients hospitalized with acute respiratory distress syndrome (ARDS) in ICU. In this case report with associated review, we present a case of a critically ill patient with COVID-19 managed in ICU for ARDS. Psychiatry was
    Document: There have been increasing reports of neuropsychiatric presentations and symptoms of COVID-19, more commonly seen in severely ill patients. Delirium, which is highly prevalent in general intensive care unit (ICU) populations, is expected to be frequent and prominent in COVID-19 patients hospitalized with acute respiratory distress syndrome (ARDS) in ICU. In this case report with associated review, we present a case of a critically ill patient with COVID-19 managed in ICU for ARDS. Psychiatry was consulted for management of her hyperactive delirium, likely complicated by environmental factors inherent in management of COVID-19 patients as well as the use of multiple sedatives. Patient was successfully managed by psychiatry with a combination of high-dose melatonin, suvorexant, guanfacine, intravenous haloperidol, and intravenous valproic acid. In addition to case presentation, we discuss a proposed delirium pathophysiology in COVID-19 associated delirium and a systematized approach to evaluation and management of such patients.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and long term cognition: 1
    • acute ards respiratory distress syndrome and lumbar puncture: 1, 2
    • acute ards respiratory distress syndrome and lung airspace: 1, 2
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute care and lumbar puncture: 1, 2
    • acute care and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute effect and long term cognition: 1
    • acute effect and lumbar puncture: 1
    • acute effect and lymphocyte count: 1
    • acute management and lumbar puncture: 1, 2, 3
    • acute management and lung airspace: 1, 2
    • acute management and lymphocyte count: 1, 2, 3
    • acute management available and lymphocyte count: 1
    • acute sars respiratory syndrome coronavirus and long term cognition: 1
    • acute sars respiratory syndrome coronavirus and lumbar puncture: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars respiratory syndrome coronavirus and lung airspace: 1
    • acute sars respiratory syndrome coronavirus and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission day and lumbar puncture: 1, 2, 3, 4, 5
    • admission day and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25